| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1994;57:1395-1401
© 1994 The Society of Thoracic Surgeons
Thoracic Oncology Research Laboratory, Section of Thoracic Surgery, Department of Surgery, Section of Pulmonary/Critical Care, Department of Medicine, Department of Molecular and Cellular Engineering, and Institute for Human Gene Therapy, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
* Address reprint requests to Dr Albelda, Thoracic Oncology Research Laboratory, Hospital of the University of Pennsylvania, 36th and Spruce, Maloney Bldg, Rm 809, Pliladelphia, PA 19104.
Malignant mesothelioma remains a frustrating clinical problem with uniformly poor responses to current therapeutic regimens. However, the localized nature of the disease, the potential accessibility of the tumor, and the relative lack of distant metastases make it a particularly attractive candidate for somatic gene therapy. The purpose of this study was to evaluate the ability of an adenoviral vector system to transfer genetic material to human mesothelioma cells in vitro and in vivo. Using a replication-deficient recombinant adenovirus carrying the Escherichia coli lacZ market gene, we found that human mesothelioma cell lines were susceptible to adenovirus infection. Furthermore, surprisingly effective gene transfer was accomplished within tumor implants of human mesothelioma growing within the peritoneal cavity c. immunodeficient mice after intraperitoneal administration of virus. These studies demonstrate that adenoviral vectors hold promise as vehicles to deliver gene therapy in human malignant mesothelioma.
This article has been cited by other articles:
|
|
 |
|
  S. Busacca, S. Germano, L. De Cecco, M. Rinaldi, F. Comoglio, F. Favero, B. Murer, L. Mutti, M. Pierotti, and G. Gaudino MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications Am. J. Respir. Cell Mol. Biol., March 1, 2010; 42(3): 312 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sartore-Bianchi, F. Gasparri, A. Galvani, L. Nici, J. W. Darnowski, D. Barbone, D. A. Fennell, G. Gaudino, C. Porta, and L. Mutti Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma Clin. Cancer Res., October 1, 2007; 13(19): 5942 - 5951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sako, J. Kitayama, H. Koyama, H. Ueno, H. Uchida, H. Hamada, and H. Nagawa Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric Cancer Cancer Res., May 15, 2004; 64(10): 3624 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Martin-Martinez, M. Stoenoiu, C. Verkaeren, O. Devuyst, and C. Delporte Recombinant adenovirus administration in rat peritoneum: endothelial expression and safety concerns Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1293 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Kruklitis, S. Singhal, P. Delong, V. Kapoor, D. H. Sterman, L. R. Kaiser, and S. M. Albelda Immuno-gene therapy with interferon-{beta} before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Devin, Y.C. G. Lee, R. W. Light, and K. B. Lane Pleural Space as a Site of Ectopic Gene Delivery: Transfection of Pleural Mesothelial Cells With Systemic Distribution of Gene Product Chest, January 1, 2003; 123(1): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsukuda, R. Wiewrodt, K. Molnar-Kimber, V. P. Jovanovic, and K. M. Amin An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell Cancer Res., June 1, 2002; 62(12): 3438 - 3447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Smythe Gene therapy for thoracic disease: practice, promise, and pragmatism Ann. Thorac. Surg., March 1, 2002; 73(3): 704 - 706. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wiewrodt, A. P. Thomas, L. Cipelletti, M. Christofidou-Solomidou, D. A. Weitz, S. I. Feinstein, D. Schaffer, S. M. Albelda, M. Koval, and V. R. Muzykantov Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells Blood, February 1, 2002; 99(3): 912 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Odaka, D. H. Sterman, R. Wiewrodt, Y. Zhang, M. Kiefer, K. M. Amin, G.-P. Gao, J. M. Wilson, J. Barsoum, L. R. Kaiser, et al. Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-{beta} Gene Therapy Is Attributable to Induction of Systemic Immunity Cancer Res., August 1, 2001; 61(16): 6201 - 6212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Rogers, S. F. McLean, R. L. Kirkman, D. Della Manna, S. J. Bright, C. C. Olsen, A. D. Myracle, M. S. Mayo, D. T. Curiel, and D. J. Buchsbaum In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector Clin. Cancer Res., February 1, 1999; 5(2): 383 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schwarzenberger, D. Lei, S. M. Freeman, P. Ye, A. Weinacker, C. Theodossiou, W. Summer, and J. K. Kolls Antitumor Activity with the HSV-tk-gene-modified Cell Line PA-1-STK in Malignant Mesothelioma Am. J. Respir. Cell Mol. Biol., August 1, 1998; 19(2): 333 - 337. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Roth and R. J. Cristiano Gene Therapy for Cancer: What Have We Done and Where Are We Going? J Natl Cancer Inst, January 1, 1997; 89(1): 21 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, H. Laks, D. C. Drinkwater, A. Blitz, L. Lam, Y. Shiraishi, P. Chang, T. A. Drake, and A. Ardehali CARDIAC GENE TRANSFER BY INTRACORONARY INFUSION OF ADENOVIRUS VECTOR--MEDIATED REPORTER GENE IN THE TRANSPLANTED MOUSE HEART J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 246 - 252. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Kucharczuk, A. A. Elshami, H. B. Zhang, W. R. Smythe, H. C. Hwang, J. S. Tomlinson, K. M. Amin, L. A. Litzky, S. M. Albelda, and L. R. Kaiser Pleural-based mesothelioma in immune competent rats: A model to study adenoviral gene transfer Ann. Thorac. Surg., September 1, 1995; 60(3): 593 - 598. [Abstract] [PDF]
|
|
|
|
|
|
H. I. Pass Malignant pleural mesothelioma: The thoracic surgeon and gene therapy Ann. Thorac. Surg., June 1, 1994; 57(6): 1383 - 1384. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
